Synonym
T-1105; T 1105; T1105.
IUPAC/Chemical Name
3-oxo-3,4-dihydropyrazine-2-carboxamide
InChi Key
SZPBAPFUXAADQV-UHFFFAOYSA-N
InChi Code
InChI=1S/C5H5N3O2/c6-4(9)3-5(10)8-2-1-7-3/h1-2H,(H2,6,9)(H,8,10)
SMILES Code
O=C1C(C(N)=O)=NC=CN1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
T-1105, structural analogue of T-705, inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite.
In vitro activity:
However, T-705 and T-1105 significantly reduced the cell death rate in the test wells compared with that in the mock-treated ZIKV-infected cells (P < 0.05, two-tailed Student’s t-test). The EC50 of T-705 was 110.9 ± 13.1 μM and that of T-1105 was 97.5 ± 6.8 μM. The dose-response curve results are shown in Fig. 2.
Reference: Arch Virol. 2017; 162(9): 2847–2853. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563514/
In vivo activity:
The animals in the control group showed typical signs of FMD, such as fever, vesicles on their feet and lameness, but no clinical signs of FMD were observed in T-1105-treated pigs throughout the experiment. Viremia was effectively reduced to below the levels of detection and the increase of anti-FMD antibody titers was suppressed after T-1105 treatment, suggesting that the virus replication was effectively inhibited by this compound in the infected pigs.
Reference: Antiviral Res. 2009 Jun; 82(3): 95–102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127082/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
25.0 |
179.91 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
139.11
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Qiu L, Patterson SE, Bonnac LF, Geraghty RJ. Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006421. doi: 10.1371/journal.pntd.0006421. PMID: 29672522; PMCID: PMC5929572.
2. Cai L, Sun Y, Song Y, Xu L, Bei Z, Zhang D, Dou Y, Wang H. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853. doi: 10.1007/s00705-017-3436-8. Epub 2017 Jun 8. PMID: 28597088; PMCID: PMC5563514.
3. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. doi: 10.1016/j.antiviral.2009.02.198. Epub 2009 Mar 6. PMID: 19428599; PMCID: PMC7127082.
In vitro protocol:
1. Qiu L, Patterson SE, Bonnac LF, Geraghty RJ. Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006421. doi: 10.1371/journal.pntd.0006421. PMID: 29672522; PMCID: PMC5929572.
2. Cai L, Sun Y, Song Y, Xu L, Bei Z, Zhang D, Dou Y, Wang H. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853. doi: 10.1007/s00705-017-3436-8. Epub 2017 Jun 8. PMID: 28597088; PMCID: PMC5563514.
In vivo protocol:
1. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. doi: 10.1016/j.antiviral.2009.02.198. Epub 2009 Mar 6. PMID: 19428599; PMCID: PMC7127082.
1: Huchting J, Vanderlinden E, Winkler M, Nasser H, Naesens L, Meier C. Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and its De-Fluoro-Analogue T-1105 as Potent Influenza Virus Inhibitors. J Med Chem. 2018 Jun 15. doi: 10.1021/acs.jmedchem.8b00617. [Epub ahead of print] PubMed PMID: 29906392.
2: Qiu L, Patterson SE, Bonnac LF, Geraghty RJ. Nucleobases and corresponding nucleosides display potent antiviral activities against dengue virus possibly through viral lethal mutagenesis. PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006421. doi: 10.1371/journal.pntd.0006421. eCollection 2018 Apr. PubMed PMID: 29672522; PubMed Central PMCID: PMC5929572.
3: Cai L, Sun Y, Song Y, Xu L, Bei Z, Zhang D, Dou Y, Wang H. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853. doi: 10.1007/s00705-017-3436-8. Epub 2017 Jun 8. PubMed PMID: 28597088; PubMed Central PMCID: PMC5563514.
4: de Avila AI, Moreno E, Perales C, Domingo E. Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. Virus Res. 2017 Apr 2;233:105-112. doi: 10.1016/j.virusres.2017.03.014. Epub 2017 Mar 18. PubMed PMID: 28322918.
5: De Vleeschauwer AR, Lefebvre DJ, Willems T, Paul G, Billiet A, Murao LE, Neyts J, Goris N, De Clercq K. A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds. Transbound Emerg Dis. 2016 Apr;63(2):e205-12. doi: 10.1111/tbed.12255. Epub 2014 Aug 28. PubMed PMID: 25164494.
6: Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol. 2013 Oct;84(4):615-29. doi: 10.1124/mol.113.087247. Epub 2013 Aug 1. PubMed PMID: 23907213.
7: Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. doi: 10.1016/j.antiviral.2009.02.198. Epub 2009 Mar 6. Review. PubMed PMID: 19428599.
